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Abstract
It is common practice in genome-wide association studies (GWAS) to focus on the relationship between disease risk and
genetic variants one marker at a time. When relevant genes are identified it is often possible to implicate biological
intermediates and pathways likely to be involved in disease aetiology. However, single genetic variants typically explain
small amounts of disease risk. Our idea is to construct allelic scores that explain greater proportions of the variance in
biological intermediates, and subsequently use these scores to data mine GWAS. To investigate the approach’s properties,
we indexed three biological intermediates where the results of large GWAS meta-analyses were available: body mass index,
C-reactive protein and low density lipoprotein levels. We generated allelic scores in the Avon Longitudinal Study of Parents
and Children, and in publicly available data from the first Wellcome Trust Case Control Consortium. We compared the
explanatory ability of allelic scores in terms of their capacity to proxy for the intermediate of interest, and the extent to
which they associated with disease. We found that allelic scores derived from known variants and allelic scores derived from
hundreds of thousands of genetic markers explained significant portions of the variance in biological intermediates of
interest, and many of these scores showed expected correlations with disease. Genome-wide allelic scores however tended
to lack specificity suggesting that they should be used with caution and perhaps only to proxy biological intermediates for
which there are no known individual variants. Power calculations confirm the feasibility of extending our strategy to the
analysis of tens of thousands of molecular phenotypes in large genome-wide meta-analyses. We conclude that our method
represents a simple way in which potentially tens of thousands of molecular phenotypes could be screened for causal
relationships with disease without having to expensively measure these variables in individual disease collections.
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Introduction
It is common practice within genome-wide association studies
(GWAS) and their meta-analyses to focus on the relationship
between disease risk and single nucleotide polymorphisms (SNPs)
one genetic variant at a time. This strategy is often very
informative in terms of identifying biological intermediates and/
or pathways likely to be important in disease pathogenesis. For
example, the association between coronary heart disease and
genetic variants located within genes regulating levels of low
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density lipoprotein (LDLc) [1–4], confirms low density cholesterol as
a key player in the aetiology of coronary heart disease. Likewise, it is
now common practice to follow up disease associated variants in
gene expression studies. If the disease associated variant is also
related to levels of gene expression in a relevant target tissue, then
this is often interpreted as prima facie evidence that the variant
exerts at least part of its functional effect by altering transcription
levels of that gene, which downstream subsequently predisposes to
disease. Using a similar rationale, the absence of genetic association
can also be informative in providing evidence against biological
intermediates playing a role in disease aetiology so long as the study
is adequately powered. For example, Mendelian Randomization [5]
studies have shown that variants within the CRP gene appear to be
unrelated to hypertension, type 2 diabetes and coronary heart
disease, suggesting that CRP is unlikely to be important in the
aetiology of these conditions, but rather that observational
associations between CRP and these diseases are more likely to
represent confounding and/or reverse causation [6–8].
Given that genetic variants can highlight potentially important
relationships between biological mediators/environmental expo-
sures and disease, it would seem a worthwhile exercise to screen
GWAS of as many diseases as possible for SNPs known to be
related to biological intermediates. However single variants
typically explain only a small proportion of the variance in these
biological intermediates, and so it might be expected that the SNPs
indexing these variables, may not show strong evidence of
association, particularly in smaller GWAS. Potentially, a more
powerful strategy would be to look at the combined effect of
several genetic variants that together explain greater variance in
the intermediate of interest, and consequently may be more
strongly related to disease. In other words, our idea is to invert the
GWAS paradigm. Rather than investigate SNPs which are
associated with disease and then see if they are related to
intermediates, take combinations of SNPs known to be related to
biological intermediates and test to see if they are related to
disease.
One might ask the obvious question, if the interest is on the
relationship between biological intermediates and disease, then
why not measure these quantities directly in the observational
studies themselves? Whilst this is certainly possible, and may have
many benefits, we argue that our strategy has several advantages
that make it a worthwhile approach to consider. First, our method
provides a way to efficiently screen many different biological
intermediates quickly and inexpensively without having to
measure them in the disease cohort of interest. All that is required
is knowledge of the genetic variants that relate to the biological
intermediate of interest and that these same SNPs have been
genotyped on a sample of disease cases and controls (in practice
this will most likely mean using GWAS data). An added benefit is
that due to the existence of GWAS consortia, the strategy could in
theory be applied to the tens of thousands of individuals that have
been genotyped as part of these consortia making the method
potentially very powerful.
Second, the same allelic scores could be used to screen an
unlimited number of different collections and/or diseases so long
as (genome-wide) SNP data is available in these cohorts and
includes variants related to the intermediates of interest. Third,
allelic scores are more likely to represent individuals’ lifetime
exposure to the factor of interest rather than a one off
measurement of the intermediate, which in contrast, might be
susceptible to considerable measurement error and time depen-
dency [2]. Fourth, whilst measurements of biological intermediates
in disease populations may be influenced by medications and/or
reverse causality, we expect that genetic variants/allele scores are
not influenced by many confounders (including medications and/
or reverse causality), although we stress that even in this case,
correlation does not necessarily imply causation.
Finally, and most importantly, the approach is in theory
extendable to any variable of interest, not just single biological
intermediates, but potentially multiple molecular phenotypes as
well (e.g. levels of gene expression, methylation, metabolomic data
etc). This means that in principle tens of thousands of molecular
phenotypes could be screened simultaneously for possible causal
relationships with the disease of interest, and in so doing flag
biological pathways that deserve attention. These associations
could then be followed up in more detail e.g. by formal Mendelian
Randomization to investigate the possibility of a causal relation-
ship further [5]. We emphasize, however, that the approach will
not identify observational associations which are due to environ-
mental factors which affect both the intermediate and disease, nor
will it identify associations which are due to the disease causing the
intermediate (i.e. reverse causality). This is advantageous if one is
only interested in factors which potentially cause disease, but will
also by definition exclude non-causal associations which could
potentially be of utility such as non-causal biomarkers. For
example, assuming that elevated levels of CRP is not a
contributing causal factor for coronary heart disease [8], then
genetic variants which index CRP, should not be related to
coronary heart disease, even though levels of CRP may serve as a
useful biomarker of disease risk.
One obvious limitation of what we have proposed so far is that
the genetic variants related to the biological intermediate need to
be known a priori in order for the approach to work. In addition, in
the case of intermediates where known variants exist, they may
explain only a small amount of the total phenotypic variance in
that variable. However, we and others have previously shown that
genome-wide allelic scores generated by simply counting up
hundreds of thousands of anonymous ‘‘risk’’ alleles in genome-
wide SNP data are capable of explaining meaningful amounts of
phenotypic variance in traits of interest [9,10]. Our idea is to use
these genome-wide allelic scores in situations where there are no
known confirmed genetic variants and/or in situations where the
Author Summary
The standard approach in genome-wide association
studies is to analyse the relationship between genetic
variants and disease one marker at a time. Significant
associations between markers and disease are then used
as evidence to implicate biological intermediates and
pathways likely to be involved in disease aetiology.
However, single genetic variants typically only explain
small amounts of disease risk. Our idea is to construct
allelic scores that explain greater proportions of the
variance in biological intermediates than single markers,
and then use these scores to data mine genome-wide
association studies. We show how allelic scores derived
from known variants as well as allelic scores derived from
hundreds of thousands of genetic markers across the
genome explain significant portions of the variance in
body mass index, levels of C-reactive protein, and LDLc
cholesterol, and many of these scores show expected
correlations with disease. Power calculations confirm the
feasibility of scaling our strategy to the analysis of tens of
thousands of molecular phenotypes in large genome-wide
meta-analyses. Our method represents a simple way in
which tens of thousands of molecular phenotypes could
be screened for potential causal relationships with disease.
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known variants explain inadequate proportions of the pheno-
typic variance in the biological intermediates of interest. In
fact, our previous work has shown that these scores can
explain more phenotypic variance than allelic scores con-
structed from confirmed variants only [9,10]. This is because
many complex phenotypes (including biological intermediates)
are influenced by hundreds, if not thousands of common
variants of small effect scattered across the genome [11,12].
There is thus considerable information in the lower part of
the genome-wide distribution of association test statistics that
could be utilized to explain more of the phenotypic variance
in the modifiable exposures of interest (i.e. SNPs that exhibit
p values.561028 which do not meet the stringent criterion
for genome-wide significance also provide important predictive
information).
In this manuscript we investigate the possibility of using
allelic scores that index biological intermediates as a method
of screening for potentially causal associations between these
variables and disease. We begin first by investigating the
ability of allelic scores to explain variance in modifiable
exposures/biological intermediates of interest in a large
population based cohort- the Avon Longitudinal Study of
Parents and Children (ALSPAC). We compare the explana-
tory ability of allelic scores constructed from confirmed
variants only, to genome-wide allelic scores generated from
up to hundreds of thousands of anonymous SNPs. In order to
investigate the properties of our approach, we attempt to
index three biological intermediates of interest where the
results of large GWAS meta-analyses are available: body mass
index (BMI), C-reactive protein (CRP) and LDLc [3,13,14].
In order to replicate our pattern of associations, we perform
the same set of analyses in an independent cohort of
Australian twins (QIMR Twins) [15,16]. We subsequently
generate these allelic scores which index BMI, CRP and
LDLc in publicly available data from the first Wellcome Trust
Case Control Consortium [17], and investigate the extent to
which the scores are associated with case control status across
seven common diseases (Bipolar disorder, Coronary Artery
Disease, Crohn’s Disease, Hypertension, Rheumatoid Arthri-
tis, Type I Diabetes, Type II Diabetes).
For several of the intermediate variable - disease pairings
there exists strong evidence of a causal relationship between the
two e.g. from randomized controlled trials, Mendelian Ran-
domization studies etc. These include LDLc with coronary heart
disease [1,18], and BMI and both coronary heart disease [19]
and type 2 diabetes [20,21]. We therefore expect that at least
some of these allelic scores indexing biological intermediates will
show association with disease, even in a relatively small sample
like the WTCCC. In contrast, for other pairings, even though
observational research has shown that the two variables are
related, the pairing is unlikely to reflect a causal effect of the
intermediate/exposure variable on the disease (e.g. CRP and
type 2 diabetes [6] or coronary heart disease [8]), and thus we
expect that allelic scores should not show correlation with
disease in these cases. If we can show that the approach
produces coherent results in situations where we are relatively
confident of a causal relationship between the intermediate and
disease, then the implication is that the method may also be
useful in those situations where we are less certain of the
underlying relationship between the variables, such as in a
screen of tens of thousands of molecular phenotypes. Finally we
investigate the power of the approach, and discuss the likely
challenges involved in scaling the strategy up to investigate tens
of thousands of molecular phenotypes.
Results
Performance of allelic scores in the ALSPAC cohort
Figures 1 through 3 display the proportion of variance in each
of the different intermediate variables (i.e. BMI, CRP, and LDLc
respectively) within the ALSPAC cohort explained by a genome-
wide allelic score of variants constructed according to different
SNP inclusion thresholds. Figure 1 shows the results for BMI when
all the observed genotypes were used in calculation of the scores
and when regions around known variants were excluded from
construction of the scores. In the case of the genome-wide scores
including the known regions, the weighted score explained from
2.3% to 4.9% of the phenotypic variance in BMI depending on
the SNP inclusion threshold, whereas the unweighted score
explained from 2.1% to 3.9% of the variance. The weighted
score explained more of the phenotypic variance in BMI than the
unweighted score across all SNP inclusion thresholds tested. In the
case of the weighted score, the proportion of variance explained
tended to be greatest when the SNP inclusion threshold was liberal
(i.e. the more SNPs included in construction of the score the
better). In contrast, the predictive ability of the unweighted score
reached a maximum at the p,0.2 selection threshold, but
decreased either side of this maximum as the threshold became
more or less conservative. Constructing an allelic score using only
the known variants explained 3.2% of the variance in BMI when
weighted and 2.3% of the variance in BMI when using an
unweighted score. Interestingly using known variants explained
smaller amounts of the phenotypic variance than that explained by
the best weighted genome-wide predictors- even with the known
regions removed.
Figure 2 shows the results for CRP levels, which appear quite
different to the results for BMI. In the case of the genome-wide
scores including the known variants, the weighted score explained
from 2.0% to 4.7% of the phenotypic variance in CRP depending
on the SNP inclusion threshold, whereas the unweighted score
explained from 0.7% to 3.4% of the variance. The weighted score
explained more of the phenotypic variance in CRP than the
unweighted score across all SNP inclusion thresholds tested. For
both the weighted and unweighted scores, the proportion of
variance explained was greatest when the SNP inclusion threshold
was conservative (i.e. only SNPs with strong evidence of
association included in construction of the score). Similarly, the
greatest variance in CRP levels was explained using a weighted
allelic score derived from the known variants only. When the
known regions were removed from the construction of the scores,
the greatest variance was explained using a SNP inclusion cut-off
of around p,0.2, whilst the addition of SNPs with higher p values
decreased the scores’ explanatory ability slightly.
Figure 3 shows the results for LDLc levels. The pattern of results
appeared similar to that for CRP in that the proportion of
variance explained was greatest when the SNP inclusion threshold
was conservative. In the case of the genome-wide scores including
the known variants, the weighted score explained from 3.2% to
5.5% of the phenotypic variance in LDLc depending on the SNP
inclusion threshold, whereas the unweighted score explained from
1.1% to 4.2% of the variance. The weighted score explained more
of the phenotypic variance in LDLc than the unweighted score
across all SNP inclusion thresholds tested. Similarly, the most
variance in LDLc levels was explained using an allelic score
derived from known variants only. When the known regions were
removed from the construction of the scores, the most variance
explained was obtained using cut-offs in the range 0.4,p,0.6,
although the inclusion of extra genotype information decreased
the scores’ explanatory ability slightly.
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We also examined the effect of pruning our data for linkage
disequilibrium (LD) before constructing the allelic scores (Figures
S1 through S3). All three variables showed similar patterns of
results, namely thinning the SNP data improved the amount of
variance explained in the biological intermediate when the SNP
inclusion threshold was conservative (low p value), but decreased
the predictive ability of genome-wide scores at liberal SNP
thresholds. The corollary was that the best prediction for CRP and
LDLc was produced at conservative SNP inclusion thresholds,
whereas the best prediction occurred for BMI at high thresholds.
In particular, the LDLc and CRP score thinned for LD showed
marked improvement over an allelic score that had not been
thinned for LD at conservative SNP inclusion thresholds.
Performance of allelic scores in the QIMR twins
replication cohort
We attempted to ‘‘replicate’’ the pattern of associations
observed in the ALSPAC cohort by performing similar analyses
in a sample of Australian twins (QIMR twins) who did not
participate in the original meta-analyses of CRP, BMI and LDL.
The results of these replication analyses are presented in Figures
S4 through S6. In general, the proportion of variance explained by
the allelic scores for these traits was lower than that explained in
ALSPAC, but the pattern of results were roughly similar (i.e.
weighted scores performed better than unweighted scores; allelic
scores consisting of known variants performed better than
genome-wide scores for LDLc and CRP, whereas genome-wide
scores explained more phenotypic variance than scores consisting
of known variants for BMI etc.; complement scores with the
known variants removed could still explain significant amounts of
the phenotypic variance etc).
Performance of allelic scores in the WTCCC
Table 1 and Tables S1 through S3 display the results of the test
of association between case-control status in the WTCCC and
weighted genome-wide allelic scores calculated from all SNPs
across the genome (i.e. the columns in Table 1 labelled ‘‘GW
Score’’), a weighted allelic score constructed from variants in
known regions which met p,561028 in the relevant GWAS
meta-analysis (i.e. the columns in Table 1 labelled ‘‘Known’’), and
a weighted genome-wide score with SNPs from known regions
removed from its construction (i.e. the columns in Table 1 labelled
‘‘Complement’’). In the case of BMI, an allelic score consisting of
known variants only showed strong evidence of being related to
type 2 diabetes in the expected direction. As the threshold for SNP
inclusion became more relaxed, the BMI score also showed
nominal evidence of association with other diseases most notably
bipolar disorder. These genome-wide scores were also very
strongly related to risk of type 2 diabetes, more so than the score
constructed from the known regions only. This is expected if the
relationship between BMI and type 2 diabetes is causal, since the
known variants explained less variation in the BMI intermediate
Figure 1. Association between polygene score and BMI measured at age nine in the ALSPAC cohort. Association between polygene
score and BMI measured at age nine using different p-value thresholds for the construction of the score in ALSPAC children (N= 5819). The lines
joining the circles display the results for allelic scores calculated by using genotyped variants from across the genome in either a weighted (unbroken
line) or an unweighted (dashed line) fashion. The lines joining the triangles display scores calculated similarly but excluding all variants +/21 MB
around 32 known BMI variants, and using either a weighted (unbroken line) or unweighted (dashed line) strategy. The histogram in the background
displays the number of SNPs involved in construction of the allelic score at each corresponding SNP inclusion threshold for the ‘‘All variants’’
condition.
doi:10.1371/journal.pgen.1003919.g001
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than the genome-wide allelic scores. The fact that the genome-
wide score with the known regions removed also showed strong
association with type 2 diabetes shows that these associations do
not solely reflect the effect of variants within FTO and other BMI
genes known to be reliably associated with type 2 diabetes.
As expected, the allelic scores indexing CRP derived from the
known regions did not show strong evidence of association with
coronary heart disease or type 2 diabetes, but did show nominal
evidence of association with the auto-immune disease rheumatoid
arthritis (Table 1). In sharp contrast, the genome-wide allelic
scores indexing CRP showed strong evidence of association with
some diseases (Table 1 and Table S2) especially types 1 and 2
diabetes, Crohn’s disease, rheumatoid arthritis and coronary heart
disease- depending on the threshold chosen for score construction
(note that almost all allelic scores were associated with increased
risk of disease). It is important to note that in most cases the
strength of evidence for association with affection status tended to
increase as the inclusion threshold became more liberal, yet the
proportion of variance explained in the biological intermediate is
likely to have decreased (Figure 2). Likewise, for some thresholds,
the unweighted score provided stronger evidence of association
with disease than the weighted score, even though the weighted
score is likely to have explained more variance in the CRP
intermediate (Figure 2 and Table S2).
The allelic scores indexing LDLc constructed from the known
regions only, were associated with coronary heart disease (in the
expected direction), but were not associated with any of the other
diseases. In contrast, the genome-wide allelic scores showed
unexpected nominal associations with hypertension (decreased
risk), type I diabetes (reduced risk), and bipolar disorder (decreased
risk) at some of the inclusion thresholds (Table S3). Similar to the
case with CRP, as the SNP inclusion threshold became more
liberal, the number of likely spurious associations increased, whilst
the proportion of variance explained in LDLc is likely to have
decreased (Figure 3).
We also examined the effect of pruning our data for LD before
constructing the allelic scores (Tables S4 through S6). Results were
similar to that obtained using un-pruned scores in that scores
constructed from known variants tended to strongly predict one
disease only (e.g. BMI score and type II diabetes, LDLc score and
coronary heart disease), whereas genome-wide scores were
associated with many different conditions. Interestingly a thinned
weighted score of robustly associated LDLc variants predicted
CHD very strongly (p = 2.361028) consistent with the enhanced
ability of this score to predict intermediate LDLc levels.
The results of our power calculations are displayed in Table 2.
As expected, power to detect association increased as the
proportion of variance explained in the biological intermediate
increased, the causal effect of the intermediate on the disease
became stronger, and as the prevalence of disease decreased. In
the case of allelic scores for BMI/CRP/LDLc comprised entirely
of known variants (which explain in the vicinity of 5% of the
Figure 2. Association between polygene score and CRP measured at age nine in the ALSPAC cohort. Association between polygene
score and CRP measured at age nine using different p-value thresholds for the construction of the score in ALSPAC children (N= 4251). The lines
joining the circles display the results for allelic scores calculated by using genotyped variants from across the genome in either a weighted (unbroken
line) or an unweighted (dashed line) fashion. The lines joining the triangles display scores calculated similarly but excluding all variants +/21 MB
around 18 known CRP variants, and using either a weighted (unbroken line) or unweighted (dashed line) strategy. The histogram in the background
displays the number of SNPs involved in construction of the allelic score at each corresponding SNP inclusion threshold for the ‘‘All variants’’
condition.
doi:10.1371/journal.pgen.1003919.g002
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Figure 3. Association between polygene score and LDLc measured at age nine in the ALSPAC cohort. Association between polygene
score and LDLc measured at age nine using different p-value thresholds for the construction of the score in ALSPAC children (N= 4251). The lines
joining the circles display the results for allelic scores calculated by using genotyped variants from across the genome in either a weighted (unbroken
line) or an unweighted (dashed line) fashion. The lines joining the triangles display scores calculated similarly but excluding all variants +/21 MB
around 37 known LDLc variants, and using either a weighted (unbroken line) or unweighted (dashed line) strategy. The histogram in the background
displays the number of SNPs involved in construction of the allelic score at each corresponding SNP inclusion threshold for the ‘‘All variants’’
condition.
doi:10.1371/journal.pgen.1003919.g003
Table 1. Association between case-control status in the WTCCC and either a weighted genome-wide score consisting of all SNPs
across the genome (‘‘GW Score’’), a weighted allelic score consisting of highly significant SNPs (p,561028) from known regions
only (‘‘Known’’), or a weighted genome-wide score consisting of all SNPs across the genome with SNPs from known regions
removed from its construction (‘‘Complement’’).
BMI CRP LDLc
GW Score Known Complement GW Score Known Complement GW Score Known Complement
Dir P Dir P Dir P Dir P value Dir P value Dir P Dir P value Dir P value Dir P
BD 2 0.051 2 0.62 2 0.026 + 0.37 + 0.11 + 0.96 2 0.049 2 0.88 2 0.059
CHD + 0.37 + 0.17 + 0.57 + 0.028 + 0.80 + 0.079 + 1.761023 + 9.261023 + 0.049
HT 2 0.76 2 0.58 + 0.76 + 0.20 + 0.23 + 0.53 2 0.011 2 0.75 2 0.012
CD 2 0.97 + 0.90 + 0.99 + 2.961024 + 0.051 + 0.011 2 0.73 2 0.76 2 0.71
RA 2 0.18 + 0.15 2 0.085 + 0.17 + 0.028 + 0.69 2 0.26 2 0.25 2 0.50
T1D 2 0.97 + 0.77 + 0.85 + 0.020 + 0.15 + 0.033 2 0.018 + 0.58 2 0.20
T2D + ,2610216 + 4.361027 + 1.8610212 + 7.661028 + 0.50 + 2.161027 + 0.66 2 0.12 + 0.48
See Tables S1 through S3 for a complete list of results.
BD= Bipolar Disorder; CHD=Coronary Heart Disease; HT =Hypertension; CD=Crohn’s Disease; RA = Rheumatoid Arthritis; T1D= Type 1 Diabetes; T2D= Type 2 Diabetes.
Dir = Direction of effect; P = P value.
doi:10.1371/journal.pgen.1003919.t001
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Table 2. Approximate power to detect association between an allelic score indexing a biological exposure and disease.
2000 Cases
3000 Controls
50000 Cases
50000 Controls
sG
2 b sL
2 Disease Prevalence Power Power
10% .1 0.1% 1% 83.8% 100%
10% .2 0.4% 1% 100% 100%
10% .5 2.5% 1% 100% 100%
10% .1 0.1% 5% 66.2% 100%
10% .2 0.4% 5% 99.7% 100%
10% .5 2.5% 5% 100% 100%
10% .1 0.1% 10% 57.0% 100%
10% .2 0.4% 10% 99.0% 100%
10% .5 2.5% 10% 100% 100%
10% .1 0.1% 20% 48.3% 100%
10% .2 0.4% 20% 97.0% 100%
10% .5 2.5% 20% 100% 100%
5% .1 0.05% 1% 55.0% 100%
5% .2 0.2% 1% 98.6% 100%
5% .5 1.25% 1% 100% 100%
5% .1 0.05% 5% 39.1% 99.1%
5% .2 0.2% 5% 92.0% 100%
5% .5 1.25% 5% 100% 100%
5% .1 0.05% 10% 32.7% 94.3%
5% .2 0.2% 10% 85.6% 100%
5% .5 1.25% 10% 100% 100%
5% .1 0.05% 20% 27.3% 81.0%
5% .2 0.2% 20% 77.4% 100%
5% .5 1.25% 20% 100% 100%
1% .1 0.01% 1% 15.4% 14.6%
1% .2 0.04% 1% 46.2% 99.9%
1% .5 0.25% 1% 99.7% 100%
1% .1 0.01% 5% 11.7% 3.0%
1% .2 0.04% 5% 32.5% 94.0%
1% .5 0.25% 5% 96.4% 100%
1% .1 0.01% 10% 10.4% 1.3%
1% .2 0.04% 10% 27.2% 80.4%
1% .5 0.25% 10% 92.2% 100%
1% .1 0.01% 20% 9.3% 0.5%
1% .2 0.04% 20% 22.8% 58.8%
1% .5 0.25% 20% 85.8% 100%
0.1% .1 0.001% 1% 6.0% 0%
0.1% .2 0.004% 1% 9.1% 0.4%
0.1% .5 0.025% 1% 31.4% 92.2%
0.1% .1 0.001% 5% 5.7% 0%
0.1% .2 0.004% 5% 7.6% 0.1%
0.1% .5 0.025% 5% 22.1% 54.7%
0.1% .1 0.001% 10% 5.5% 0%
0.1% .2 0.004% 10% 7.1% 0%
0.1% .5 0.025% 10% 18.7% 33.1%
0.1% .1 0.001% 20% 5.4% 0%
0.1% .2 0.004% 20% 6.7% 0%
0.1% .5 0.025% 20% 16% 17.5%
Mining the Human Phenome Using Allelic Scores
PLOS Genetics | www.plosgenetics.org 7 October 2013 | Volume 9 | Issue 10 | e1003919
phenotypic variance in the intermediate), we expect 2000 cases
and 3000 controls to provide good power to detect moderate to
strong causal effects of the biological intermediate on disease. In
contrast, using single variants which might typically explain 0.1%
of the phenotypic variance in the biological intermediate would
offer poor power to detect association. We expect 50000 cases and
50000 controls to provide high power to detect association in the
case of allelic scores which explain .5% of the phenotypic
variance in the biological intermediate. Similarly, allelic scores
which explain 1% of the variance in the intermediate should still
be sufficient to detect moderate or strong causal links between the
intermediate and disease in this scenario. Again testing individual
SNP variants which explain small proportions of the variance
would provide very little power to detect association.
Discussion
In this paper we investigated whether it might be possible to
correlate allelic scores which reference biological intermediates
with disease status in case control studies, and in so doing provide
proof of principle for a method which could be used to screen for
thousands of possible associations between intermediate variables
and disease. We began by demonstrating that allelic scores
explained non-trivial proportions of the phenotypic variance in
BMI, CRP, and LDLc, even when known loci were taken into
account and removed from the construction of those scores. This
result confirms the existence of many common variants of small
effect scattered across the genome that were tagged by SNPs on
the genome-wide platform, but did not reach genome-wide levels
of significance in the meta-analysis. Our results are also consistent
with studies using analogous methodologies in other complex traits
and diseases, and were a key motivating force in our development
of this approach [9,11,22].
The proportion of variance explained in CRP by a weighted
score of known variants in ALSPAC (5.1%) was similar to that
reported in the CRP meta-analysis by Dehghan et al. (2011) who
also estimate that a weighted score of confirmed variants explained
around 5% of the phenotypic variance in CRP [14]. Teslovich et
al. (2010) report that a weighted score of genome-wide significant
LDLc associated variants explained 12.2% of the phenotypic
variance in LDLc [3]. The lower figure in ALSPAC (6.6%) is
probably due to a combination of factors including the ALSPAC
analysis not being performed on fasting bloods, the ALSPAC
analysis not including secondary loci in the calculation of variance
explained by known variants, and the possibility that true
differences exist in the size and identity of genetic variants that
affect LDLc levels in adults and children. Speliotes et al. (2010)
reported that a weighted score of all known BMI associated loci
explained 1.45% of the variance in BMI [13]. The proportion of
variance explained in the ALSPAC cohort was higher, at 3.2% for
the known variants. It is unclear why the proportion of variance
explained was greater in ALSPAC but may have to do with the
fact that participants were all young children of the same age (9
years) and so there was little variation due to differences in age,
sex, puberty, growth in later life etc. In terms of the proportion of
phenotypic variance explained in the intermediate variable, a
weighted allelic score generally yielded superior performance to an
unweighted score. This was expected since weighting includes
prior information in that SNPs with large estimated effect sizes
contribute more to the overall score. We also note that in the case
of the BMI, and CRP analyses, the difference in variance
explained between using weighted and unweighted scores became
less apparent when the known SNPs (i.e. SNPs with the largest
effect sizes) were excluded from the calculations. This was also
expected since smaller effects are less likely to be estimated
precisely and hence it is more difficult to weight these SNPs
appropriately.
The SNP selection threshold producing the allelic score that
explained the most variance in the intermediate differed across the
variables. This is not surprising since different phenotypes have
different underlying genetic architectures and differ in the extent
to which the variants that influence them are tagged by SNPs on
genome-wide chips. In general, the best allelic scores for BMI were
produced using liberal cut-offs. In contrast, allelic scores for CRP
and LDLc tended to perform best when constructed from
conservative threshold cut-offs. A possible reason for the discrep-
ancy is that CRP and LDLc are both influenced by loci of major
effect in ALSPAC (i.e. the variants rs4420638 (R2= 2.5%,
p= 1.7610225) and rs10401969 (R2= 2.0%, p= 1.1610220)
explain disproportionately large proportions of the variance in
LDLc, whilst the variants. rs2794520 (R2= 2.4%, p= 5.2610224)
and rs4420065 (R2= 2.3%, p= 4.5610223) explain large portions
of the variance in CRP- see also the last two columns in Table S7).
At stringent p value cut-offs therefore, these scores primarily reflect
genuine quantitative trait loci of moderate effect which explain
decent proportions of the variance in these phenotypes. In
contrast, as the cut-offs become more liberal, it is likely that the
scores become contaminated by unassociated SNPs and markers
of small effect that have less precisely estimated contributions. As a
result, the amount of variance explained in the phenotype is
reduced. We note that the same pattern of association with a few
loci contributing disproportionately large effects for these pheno-
types was also seen in the QIMR twins replication cohort although
to a less pronounced degree (Table S8). A similar observation has
been noted in studies that have used genome-wide allelic scores to
predict disease status in auto-immune diseases that involve genetic
loci of large effect in the major histocompatibility region [9]. In
contrast, in the case of BMI, no single variant contributes
disproportionately to explaining trait variance (Table S7), and so
the explanatory power of the allelic scores is facilitated through the
addition of many variants of small effect scattered across the
genome [9,11,22].
Another contributing factor to the discrepancy between the
BMI and CRP/LDLc scores is that much more phenotypic
variance is explained by the residual polygenic score in the case of
BMI (,3%) than LDLc or CRP (,1%) (see the lower two lines in
Figures 1 through 3 which show the variance explained by the
polygenic scores when the effect of known loci are removed from
construction of the scores). It is unclear why this is the case, but
could be due to many factors including genuine differences in the
genetic architecture of the traits, a difference in the extent to which
loci that affect these traits are shared between adults and children
(i.e. the original GWA meta-analyses typically involve adults
whereas ALSPAC is a paediatric cohort, although the same
phenomenon was also found in the QIMR twins, all of whom are
adults), and differences in meta-analysis size (and hence power to
detect genuine effects) from which the scores were constructed (e.g.
the CRP meta-analysis was smaller than the other two studies). We
The model is parameterized in terms of the percentage of variance in the biological intermediate explained by the SNP (sG
2), the strength of the causal relationship
between the biological intermediate (b) and liability of disease, which together determine the amount of variance in disease liability explained by the SNP (sL
2), and the
prevalence of disease. Estimates of power are presented for 2000 cases and 3000 controls (a= 0.05), and for 50000 cases and controls (a= 1.161027).
doi:10.1371/journal.pgen.1003919.t002
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note that the same pattern of association is also seen in the QIMR
twins replication sample suggesting that the pattern of results is not
cohort specific.
Pruning for LD enhanced prediction of the biological interme-
diates at conservative but not liberal SNP construction thresholds.
This was most apparent for the CRP and LDLc associated allelic
scores. We argue that at conservative thresholds, the contribution
of individual variants to the biological intermediate is estimated
most precisely when data has been thinned for LD (i.e. the signal is
at its most ‘‘pure’’). In addition, such a score will also capture
secondary signals at known loci, which may help explain why the
thinned scores performed better than allelic scores consisting of
known variants only (additional secondary loci were not included
in the known variant scores in this study). However, in the case of
genome-wide allelic scores constructed from liberal thresholds, the
signal from loci of small effect scattered across the genome are not
estimated as precisely as signals from known variants, and so,
pruning for LD has the effect of removing the signal from these
scores.
Importantly we have demonstrated that genome-wide allelic
scores can still explain meaningful portions of the phenotypic
variance, even in situations where known variants have been
excluded from the calculation of the allelic score. For example, in
the case of BMI, a genome-wide allelic score still explained,3.4%
of the variance in BMI even after known regions were removed
from construction of the scores (a high figure was also noted in the
QIMR twins replication set). The exciting implication is that in the
case of other biological intermediate variables of interest for
which there are currently no known genetic variants, genome-
wide allelic scores may still be able to proxy these variables and
could subsequently be used in tests of association with diseases of
interest.
We note that the present study has benefitted from very large
genome-wide association meta-analyses from which the SNPs that
comprise the genome-wide allelic scores were selected [3,13,14]. A
recent study by Demirkan et al. (2012) found that a polygenic
score only explained 2.6% of the phenotypic variance in LDLc
[23]. Demirkan et al suggested that this low figure might have
been a consequence of the small size of the discovery sample on
which their weighting scheme was based (i.e. ,20,000 individuals
as compared to the ,100,000 individuals used in Teslovich et al
which forms the basis of this study) and consequently decreased
precision in estimating effect sizes and direction of effects. These
factors (plus the existence of some loci of large effect in ALSPAC)
may also partially explain the comparatively better predictive
ability in our study (particularly at more liberal p value inclusion
thresholds) as construction of allelic scores in ALSPAC was based
on the much larger Teslovich et al meta-analysis. Although the
proportion of variance explained in ALSPAC was greater than
that found by Demirkan et al., we note that the pattern of variance
explained across the different SNP inclusion thresholds was similar
across both studies as well as the QIMR replication set (i.e. as the
threshold becomes less stringent, less variance is explained).
In addition, all of the intermediate variables that we examined
exhibit substantial heritability. Our method relies on these
preconditions and it remains to be seen how useful the approach
will be in scenarios where the genome-wide association meta-
analysis is small and/or the variables of interest have low
heritabilities. The corollary is that although our method may
have worked adequately in the case of these three variables, it
does not necessarily follow that our success will translate to
other phenotypes and we suggest that those wishing to apply
the approach proceed with caution in its application and
interpretation.
Finally, we note that whilst we have combined a simple
threshold based SNP selection procedure with a straightforward
weighting, considerable potential exists to make the approach
more powerful by tailoring the selection of SNPs and combining
them in more optimal ways. These approaches could include
machine learning or lasso regression for example [24].
Associations between allelic scores and WTCCC disease
status
Our method successfully identified established causal relation-
ships between BMI and type 2 diabetes, and LDLc and coronary
heart disease. This is consistent with the power calculations
presented in Table 2 which suggested that 2000 cases, 3000
controls and an allelic score explaining roughly 5% of the variance
in a biological intermediate provided good power to detect
moderate to strong relationships between the intermediate and the
disease outcome. Interestingly, in the case of BMI, the genome-
wide allele score was more strongly related to type 2 diabetes than
the allelic score constructed from the known variants only. This
observation is consistent with our demonstration that the genome-
wide allelic score explained greater proportions of the variance in
BMI than the allelic score comprised from the known variants
only. In fact, even the genome-wide allelic score indexing BMI
with the regions around the known BMI SNPs removed also
correlated strongly with type 2 diabetes. Taken together these
results suggest that the BMI-type 2 diabetes association does not
solely reflect the effect of variants within FTO and other BMI
genes known to be reliably associated with type 2 diabetes, and
also further strengthens the proposition that genome-wide allelic
scores may have promise in indexing intermediates, even in
situations where there are no known variants underlying the
intermediate (i.e. as we have artificially done here by removing the
variants from the known BMI associated regions).
It is noteworthy that our method did not appear to detect other
observational associations thought to reflect causal relationships.
For example, there have been associations reported between BMI
and coronary heart disease [25], and BMI and hypertension [26].
Table 2 implies that the most probable explanation for this failure
is statistical power in that 2000 cases and 3000 controls is unlikely
to provide sufficient power to detect weaker causal relationships
between biological intermediates and disease.
Another notable finding involves the relationship between allelic
scores that index CRP levels and disease. It is interesting that the
genome-wide allelic score that indexed CRP correlated with many
of the WTCCC diseases, whereas the allelic score constructed
from the known regions only, did not. Mendelian Randomization
studies have shown that CRP is unlikely to cause several diseases to
which it had been linked including type II diabetes and coronary
heart disease, but rather the observational associations are
probably a secondary consequence of the disease itself or due to
latent confounding [6–8]. Given that the genome-wide allelic score
actually explained less variance in CRP level than the known
variant score (i.e. 2% versus 5%), we suggest that a causal effect of
CRP on the different diseases is unlikely, but rather that genetic
pleiotropy and the lack of specificity of the genome-wide allelic
score is the most likely explanation for this difference. For
example, many BMI associated SNPs are present at quite low
levels of significance in the CRP GWAS meta-analysis (Table S9),
although in this case, not at genome-wide significant levels.
Furthermore bidirectional Mendelian Randomization studies have
demonstrated that higher BMI leads to elevated CRP, not vice
versa [27]. Scores created from these SNPs would therefore show
association with CRP level, BMI and consequently (through BMI)
greater risk of type 2 diabetes. A similar explanation probably
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underlies the apparent association between the CRP genome-wide
allele score and the auto-immune diseases except the mediating
variable is likely to be some immune parameter that affects both
CRP and risk of rheumatoid arthritis/type I diabetes/Crohn’s
disease.
Similar results were also seen for the allelic scores which indexed
LDLc. Whilst the allelic score consisting of known variants only
correlated with CHD as expected, the genome-wide allelic score
showed unexpected nominal correlations with other diseases
including hypertension and type I diabetes. As the genome-wide
score explained less variance in the intermediate than the allelic
score derived from the known variants, we believe that this
association also reflects unwanted genetic pleiotropy and lack of
specificity in the genome-wide score for similar reasons alluded to
above.
These results highlight the potential advantages and disadvan-
tages of using genome-wide allelic scores to index biological
intermediates. As the number of SNPs that comprise the allelic
score increases, the score may gain power in terms of explaining
variance in the exposure/mediator of interest (e.g. as in the case of
BMI and possibly also in the case of many other biological
intermediates for which no known variants exist), but the downside
is that the score potentially loses specificity and may produce
associations with disease that do not necessarily reflect causal
relationships. Our results also indicate that whilst thinning
genome-wide SNP data for LD might be useful in terms of
explaining more variance in the biological intermediate (and hence
power to detect a true causal relationship between intermediate
and disease) it is unlikely to mitigate the endemic issues of
pleiotropy and lack of specificity of the genome-wide scores (i.e.
likely spurious associations were observed with thinned data also).
A logical strategy therefore might be to use confirmed variants
only to generate allelic scores in those situations where there are
individual SNPs known to explain variance in the intermediate of
interest. In the absence of genetic pleiotropy, these allelic scores
should be powerful and specific to the biological intermediate of
interest. In contrast, in those situations where there are no variants
that are known to affect the intermediate, genome-wide allelic
scores could be employed to investigate a possible relationship with
disease. In this way a balance can be struck between maintaining
power and attempting to preserve specificity, although we note
that, even in the case of an allelic score constructed completely
from known variants, there is no guarantee that such a score will
be completely specific for the intermediate of interest and that
there will not exist other paths from SNP to disease. Thus, in the
presence of an association between an outcome of interest and an
allelic score of known variants that index an exposure, we strongly
suggest follow up using formal Mendelian Randomization
methodologies [5].
In the situation where there are no variants known to underlie
the biological intermediate of interest, formal Mendelian Ran-
domization will not be possible, and so it will be difficult to
determine whether an association between a genome-wide allelic
score and a disease of interest reflects a causal relationship. In
addition, our results suggest that lack of specificity and contam-
ination of genome-wide scores through genetic pleiotropy will
mean that many of these associations will be ‘‘spurious’’ and will
not reflect causal effects of the intermediate on the outcome.
However, it might still be possible to get some indication of
whether the data are consistent with a causal effect of the
intermediate on the disease by examining the pattern of
association across different SNP construction thresholds and
weighting schemes. For example, in the presence of a causal
influence of the biological intermediate on disease risk, we would
expect that the strongest evidence for a relationship between the
allelic score and affection status occurs at those conditions/
thresholds that simultaneously explain the greatest proportion of
phenotypic variance in the intermediate. If this pattern occurs in
the data, then the results are at least consistent with a causal effect
of the intermediate on disease risk (although this of course does not
prove a causal relationship). If this pattern of results is not present
in the data, then it suggests that the association is more likely due
to genetic pleiotropy and/or lack of specificity in the genome-wide
score. For example, in the present set of results, the strongest
evidence for associations between LDLc and coronary heart
disease occurred at those conditions where a thinned weighted
allelic score concurrently explained the greatest variance in the
intermediate phenotype, consistent with a causal relationship
between LDLc and coronary heart disease (Table S6). In contrast,
the strongest evidence for a relationship between CRP and type II
diabetes occurred at those thresholds where the variance explained
in CRP was at a minimum, suggesting a spurious relationship
between the two variables.
Whilst our approach has several similarities to Mendelian
Randomization [5], we stress that our method is designed as a
screening tool that provides preliminary evidence for a possible
causal relationship between an intermediate which may be worth
following up in focused future studies. The method is not intended
as a means of providing conclusive evidence for a causal
relationship between two variables. Specifically, our approach
does not rule out the possibility of a pleiotropic relationship
between the SNPs that index the intermediate and the disease, nor
does it rule out the possibility that an allelic score (particularly a
genome-wide allelic score) has been ‘‘contaminated’’ by SNPs as a
result of reverse causation. For example, if type 2 diabetes were to
cause an elevation of CRP levels, then it is conceivable that some
type 2 diabetes SNPs might show association in a GWAS meta-
analysis of CRP. Therefore, allelic scores indexing CRP which are
based on this GWAS meta-analysis will also show association with
type 2 diabetes even though the direction of causation may be
from the disease to the biological intermediate. The point we do
stress is that our method is useful for flagging putative causal
relationships across potentially thousands of biological intermedi-
ates, and we recommend following up interesting associations by
e.g. formal Mendelian Randomization analysis, randomized
controlled trials, mechanistic studies etc.
Possible biases
In this study we were careful to ensure that the cohorts used to
assess the amount of phenotypic variance explained in the
biological intermediates (i.e. ALSPAC and QIMR twins) were
not also present in the original discovery meta-analyses of CRP,
BMI and LDLc (NB. the QIMR twin individuals who contrib-
uted to the Teslovich et al. meta-analysis were from different
families to those used in the present study) [3]. Inclusion of the
same individuals who were in the discovery meta-analysis would
have inflated the proportion of variance explained in the
biological intermediate particularly when liberal significance
thresholds were used in construction of the genome-wide allelic
scores [28]. Likewise, we were also careful to exclude the 1958
birth cohort as a control group when examining the predictive
ability of allelic scores to determine case control status in the
WTCCC (the 1958 birth cohort contributed to the discovery
meta-analyses of BMI, LDLc and CRP). We were also able to
exclude the Wellcome Trust hypertension, coronary heart
disease, type 2 diabetes and control group results from the
original Speliotes et al. BMI meta-analysis so that the inclusion of
these groups did not bias our analyses of BMI SNPs and WT case
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control status. However, we were unable to remove the Well-
come Trust hypertension cohort from the Teslovich et al. meta-
analysis [3] so this fact should be borne in mind when
interpreting the results of these analyses (although LDLc score
failed to significantly correlate with hypertension status across
most thresholds).
Extending the allelic score approach to data mine
thousands of molecular phenotypes
The most exciting implication of our work, is that the approach
could be successfully extended to examine hundreds of thousands
of molecular phenotypes. GWAS of molecular technologies that
target the transcriptome [29], metabolome [30], and most
recently, the methylome [31] have begun to appear in the
literature with increasing frequency. Allelic scores which index
levels of transcription, methylation and levels of metabolites etc
could be constructed and subsequently used as instruments to
screen for possible associations with hundreds of traits and
diseases, in tens of thousands of individuals. Our power
calculations demonstrate that such an approach is realistic in the
very large GWA met-analyses that currently exist.
Conclusions
When genetic variants that affect a biological intermediate
are known a priori, we recommend using these SNPs exclusively
to construct allelic scores that proxy for the biological
intermediate of interest. If a subset of the known variants is
specific for the intermediate, then we recommend using these
variants solely in construction of the allelic score and excluding
variants with pleiotropic effects that may complicate interpre-
tation of the effect. This minimizes (although certainly does not
abolish) concerns due to genetic pleiotropy and lack of
specificity. We stress that a positive association between an
allelic score of known variants and disease does not prove a
causal relationship between the intermediate and disease but
merely flags an interesting association that may be worthy of
follow up by more formal methods (e.g. proper Mendelian
Randomization analysis etc).
In the situation where the identity of individual genetic variants
affecting the biological intermediate are unknown, a genome-wide
allelic score can be used to proxy the trait of interest. In this
situation we recommend employing the strictest p-value inclusion
threshold in construction of the genome-wide allelic score that
maximizes the amount of variance explained in the biological
intermediate. In this way, the amount of variance explained in the
intermediate is maximized, whilst simultaneously attempting to
minimize the number of SNPs with pleiotropic effects that go into
construction of the score. Since the potential for spurious
association due to pleiotropy is particularly high when using
hundreds or thousands of SNPs, we recommend that if genome-
wide scores are used, that their results are cautiously interpreted
and followed up with care.
In conclusion, whilst genome-wide association studies have
identified thousands of genetic variants underlying complex
traits and diseases, a criticism of the approach has been that in
many cases, knowledge of the risk variants underlying disease
has yet to be translated into interventions or information that
directly impacts clinical medicine and public health. Our idea is
to use allelic scores that proxy biological intermediates to data
mine genome-wide association studies. We would argue that our
simple approach is an easy to understand statistical method
which has the potential to identify possible causal relationships
between these variables and disease outcomes, and through this,
translate the findings from genetic research into information
that is relevant to public health as in the case of Mendelian
Randomization studies [32]. Our results suggest that our
approach may even be possible in the case of biological
intermediates where confirmed genetic variants are unknown a
priori through the application of genome-wide allelic scores. Our
method has the potential to revolutionize the way exposure-
disease associations are identified in observational epidemiolog-
ical studies and ensure that the considerable investment in
genome-wide association studies over the past decade is
maximized in terms of public health impact.
Materials and Methods
Participants
ALSPAC Cohort: ALSPAC is a population-based birth cohort
study consisting initially of over 13 000 women and their children
recruited in the county of Avon, UK in the early 1990s [33,34].
Both mothers and children have been extensively followed from
the mothers’ early pregnancy onwards using a combination of self-
reported questionnaires, medical records and physical examina-
tions. DNA has been extracted for 10121 of the children from this
cohort. Ethical approval for the study was obtained from the
ALSPAC Law and Ethics Committee (IRB# 00003312) and the
Local Research Ethics Committees (Bristol and Weston, South-
mead, and Frenchay Health Authorities). Written informed
consent was obtained from all participants in the study. Parents
provided written informed consent for their child. Children’s
standing height at age 9 years was measured using a Harpenden
Stadiometer. Weight was quantified using a Tanita Body Fat
Analyser at the same age. Body mass index (BMI) was calculated
as weight in kilograms divided by height in metres squared. Non-
fasting blood samples were taken using standard procedures when
the children were age 9 years, with samples immediately spun and
frozen at 280uC. The measurements were assayed in 2008 after a
median of 7.5 years in storage with no previous freeze–thaw cycles
during this period. Plasma lipids (total cholesterol, triglycerides,
and HDL cholesterol) were performed by modification of the
standard Lipid Research Clinics Protocol using enzymatic
reagents for lipid determination. C-reactive protein was measured
by automated particle-enhanced immunoturbidimetric assay
(Roche UK, Welwyn Garden City, UK). All assay coefficients of
variation were ,5%. All variables were inverse normal trans-
formed for males and females separately.
QIMR Twins Replication Cohort: Data for Australian subjects
were obtained from adult participants in twin and family studies
conducted by the Queensland Institute of Medical Research
[15,16,35]. BMI was calculated from clinically measured height
and weight supplemented with self-report for those participants
where clinical measurements were not available. CRP and LDL-C
(calculated from the Friedewald equation) measurements were
performed using Roche methods on Hitachi 917 or Modular P
analysers. The data used here represent 4781, 2767 and 2630
individuals who had genome-wide SNP information and informa-
tion on BMI, CRP and LDLc respectively. A maximum of one
individual per family was used in these analyses, yielding a set of
unrelated individuals who had not contributed any data to the
previous BMI, CRP or LDLc meta-analyses.
WTCCC: We employed previously published data from the
WTCCC in order to test the association between allelic scores
and disease status [17]. Briefly, the WTCCC is a GWAS invol-
ving individuals with one of seven diseases: bipolar disorder
(1868 individuals), coronary heart disease (1926 individuals),
Crohn’s disease (1748 individuals), hypertension (1952
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individuals), rheumatoid arthritis (1860 individuals), type I
diabetes (1963 individuals) or type II diabetes (1924 individuals),
as well as a common set of 1478 unselected controls from the 1958
British Birth Cohort and 1458 from the National Blood Service.
Genotyping
ALSPAC: A total of 9912 ALSPAC children were genotyped
using the Illumina HumanHap550 quad genome-wide SNP
genotyping platform by the Wellcome Trust Sanger Institute,
Cambridge, UK and the Laboratory Corporation of America,
Burlington, NC, USA. Individuals were excluded from further
analysis on the basis of having incorrect sex assignments; minimal
or excessive heterozygosity (,0.320 and .0.345 for the Sanger
data and ,0.310 and .0.330 for the LabCorp data); dispropor-
tionate levels of individual missingness (.3%); evidence of cryptic
relatedness (.10% IBD) and being of non-European ancestry (as
detected by a multidimensional scaling analysis seeded with
HapMap 2 individuals, EIGENSTRAT analysis revealed no
additional obvious population stratification and genome-wide
analyses with other phenotypes indicate a low lambda). The
resulting data set consisted of 8365 individuals and 488311
autosomal SNPs. SNPs with a minor allele frequency of ,1% and
call rate of ,95% were removed. Furthermore, only SNPs which
passed an exact test of Hardy–Weinberg equilibrium (p.561027)
were considered for analysis. Of these 8365 individuals, 5819 had
BMI data, and 4251 had CRP and LDLc levels measured. In
order to investigate the effect of specific SNPs from GWAS meta-
analyses of BMI, CRP, and LDLc we used autosomal genotypic
data that had been imputed using Markov Chain Haplotyping
software (MACH v.1.0.16) and phased haplotype data from CEU
individuals (Hapmap release 22, Phase II NCBI B36, dbSNP 126).
QIMR Twins Replication Cohort: Genotyping within this
cohort was performed in multiple waves using Illumina SNP chips
(317K ; 370K duo; 370K quad; 610K; or 660K). Details of
cleaning, data merging and imputation protocols have been
described extensively in Medland et al. (2009) [35]. Briefly, each
wave of genotyping was screened for call rate and quality,
following this the data sets were merged and checked for calling
consistency using a series of overlapping samples which were
included in multiple genotyping waves. The merged genotype sets
were then screened for call rate ,95% and quality (GenCall..7),
minor allele frequency ,1%, and Hardy–Weinberg equilibrium
(p.161026). In addition, as the QIMR cohort contains data from
nuclear families (including parents, twins, siblings, spouses and
offspring) we also screened the genotypes to confirm reported
relationships, check for unknown relatedness and identify Men-
delian errors taking the conservative approach of dropping a SNP
for all family members if the erroneous genotype could not be
identified.
WTCCC: Individuals were genotyped at the Wellcome Trust
Sanger Institute, Cambridge, UK using the Affymetrix 500K SNP
chip. Genotype data were subjected to rigorous quality control
measures (SNPs with MAF ,1%, missing rate .5% or Hardy
Weinberg p,561028 were excluded) in order to remove poor
quality SNPs as well as putatively related individuals and those of
non-European ancestry (for a full description of the cohorts see the
original WTCCC article [17]).
Construction and testing of allelic scores
We were interested in whether allelic scores constructed from
hundreds of thousands of SNPs across the genome might produce
powerful instruments that explained larger proportions of the
phenotypic variance in biological intermediates than allelic scores
derived from combinations of known variants. We used recent
large scale GWAS meta-analyses of BMI [13], CRP [14], and
LDLc [3] to select SNPs that went into the construction of the
genome-wide allelic scores. In other words, SNPs that met a
certain p-value threshold in the GWAS meta-analysis were then
used to construct an allelic score in the ALSPAC dataset (NB.
ALSPAC was not part of the BMI, CRP, or LDLc meta-analyses).
Genome-wide allelic scores were constructed from directly
genotyped SNPs in the ALSPAC children’s samples using the
profile scoring routine in the PLINK software package [36]. The
profile score for each individual was derived as a sum across SNPs
of the number of putative increaser alleles (0,1 or 2) at each locus
multiplied by a weight. In the case of missing genotype data for an
individual, expected dosage based upon allele frequency of the
increaser alleles at the locus was used instead of the number of
increaser alleles. We investigated two methods of constructing
allelic scores- an unweighted strategy where each copy of the
increaser allele provided a score of one, and a strategy where the
contribution of each SNP was weighted by its regression coefficient
from the relevant genome-wide meta-analysis [9]. We refer to
these strategies as the ‘‘unweighted’’ and ‘‘weighted’’ strategies
respectively. Allelic scores were constructed for BMI, CRP, and
LDLc separately. We also constructed allelic scores using 32
variants known to affect BMI [13], 18 variants known to affect
CRP levels [14], and 37 variants known to affect LDLc levels [3]
(Table S7). These analyses were based on best guess genotypes
from imputation using Markov Chain Haplotyping software
(MACH v.1.0.16) and phased haplotype data from CEU
individuals (Hapmap release 22, Phase II NCBI B36, dbSNP
126) as described previously.
In order to determine the amount of variance explained in the
biological intermediates using different strategies, we constructed
allelic scores using seventeen different p value inclusion thresholds
from the GWAS meta-analyses ranging from liberally including all
SNPs, to including only those SNPs that met a stringent genome-
wide significant criterion of p,561028. In order to separate the
effect of known genetic variation from residual polygenic variation
scattered across the genome, we also constructed genome-wide
allelic scores using the strategies above, but excluding SNPs within
one megabase either side of known variants (i.e. 32 regions in the
case of allelic scores indexing BMI; 18 regions in the case of allelic
scores indexing CRP; and 37 regions in the case of allelic scores
underlying LDLc- for a complete list of loci, please see Table S7)
and refer to these analyses as the ‘‘Complement’’ conditions.
Child’s phenotype (i.e. BMI, CRP or LDLc) was then regressed on
allelic score to determine the percentage of variance explained by
each of the scores. Similar analyses were also performed in the
QIMR twins cohort in order to test how robust the observed
patterns of associations were except that all analyses involving
‘‘known’’ variants used genotypic dosages rather than best guess
genotypes.
We also examined the effect that thinning the SNP data for LD
had on the predictive ability of the scores. We employed the ‘‘LD
based results clumping’’ routine from the PLINK software package
[36] to generate the thinned data. Briefly, this routine orders the
GWA meta-analysis association p values from strongest to weakest.
SNPs are then selected in this order, with the proviso that a variant
cannot be included, if it is in LD with a previously selected SNP.
For the purposes of this analysis we defined LD as the variants
being r2.0.2 and within 250 kb of each other.
The ability of the allelic scores to predict case control status was
tested using data from the WTCCC. Several disease groups from
the WTCCC were present in the original BMI discovery meta-
analysis [13]. Because of the possibility of inducing bias into the
results because of this, these groups were removed and the
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Speliotes et al. BMI meta-analysis repeated according to the same
protocols as outlined in the original paper [13]. In addition, since
the 1958 Birth Cohort controls were also included in the original
meta-analyses of CRP and LDL, we removed these individuals
from the WTCCC control set (i.e. only individuals from the
National Blood Donors Study remained as controls). Case-control
status for each disease was regressed on allelic score and the
direction of effect and p value were recorded. We tested a
weighted genome-wide score consisting of all variants across the
genome (unweighted in the case of LDLc), an allelic score
consisting of variants from known regions only (i.e. SNPs that met
p,561028 in the meta-analysis of the relevant phenotype), and a
weighted genome-wide allelic score with known variants (+/
2500 KB) removed from the score’s construction. This was to
contrast the performance of a completely agnostic strategy (i.e.
utilizing all the SNPs) versus the strategy of only using known
regions in construction of the scores. Finally, we examined the
performance of LD pruning (as defined above) on the ability of
weighted allelic scores to predict case-control status in the
WTCCC dataset.
Power calculations
In order to investigate the power of our approach, we
assumed the standard liability threshold model in which a
continuous normal distribution of liability underlies risk of
disease. Under this model, individuals who are affected have a
liability exceeding a certain threshold, the value of which being
determined by the prevalence of the disease in the population.
In the situation where a SNP (or an allelic score of SNPs) affects
a biological intermediate which then in turn affects likelihood of
disease, power to detect association between the SNP and
disease is determined by (a) the proportion of variance in the
biological intermediate explained by the allelic score (denoted
by sG
2), (b) the strength of the causal relationship between the
intermediate and the disease (denoted by b) which together with
sG
2 determines the proportion of liability in the disease that is
explained by the SNP (denoted by sL
2), (c) the disease
prevalence, (d) the sample size of the case-control study in
which the test is performed, and (e) the type I error level.
We calculated power using the ‘‘Case-control for threshold-
selected quantitative traits’’ module of the genetic power
calculator (c.f. http://pngu.mgh.harvard.edu/,purcell/gpc/
qcc.html; [37]) which approximates power in this situation, a
difference being that power is calculated assuming a single
equally frequent allele rather than a continuous allelic score. We
calculated power to detect association using 2000 cases and 3000
controls assuming a type I error level of a=0.05 (these conditions
mimic the BMI analyses in the current manuscript and therefore
provide an indication of whether significant results are likely to
reflect true effects). We also investigated what our power might be
if we scaled our strategy up to investigate hundreds of thousands
of molecular phenotypes (e.g. 450000 methylation sites on the
Illumina 450K array) in a large genome-wide meta-analysis. We
therefore calculated power to detect association assuming a
conservative type I error level of a=0.05/450000= 1.161027 in
50000 cases and controls, which reflects the current sample size
of some of the larger international GWAS consortia. We
investigated the effect of varying the amount of variance the
allelic score explained in the biological intermediate (sG
2 = 10%,
5%, 1%, 0.1%), the strength of relationship (i.e. linear regression
coefficient) between the intermediate and underlying disease
liability (b=0.1, 0.2 or 0.5), and the prevalence of disease
(K= 1%, 5%, 10%, 20%) in both scenarios.
Supporting Information
Figure S1 Association between polygene score and BMI
measured at age nine in the ALSPAC cohort before and after
pruning for linkage disequilibrium. Association between poly-
gene score and BMI measured at age nine using different p-
value thresholds for the construction of the score in ALSPAC
children (N= 5819). The lines joining the circles display the
results for weighted allelic scores calculated by using genotyped
variants from across the genome before (unbroken line) and
after pruning for linkage disequilibrium (dashed line). The
histogram in the background displays the number of SNPs
involved in construction of the allelic score for the ‘‘All
variants’’ condition at each corresponding SNP inclusion
threshold.
(PDF)
Figure S2 Association between polygene score and CRP
measured at age nine in the ALSPAC cohort before and after
pruning for linkage disequilibrium. Association between polygene
score and CRP measured at age nine using different p-value
thresholds for the construction of the score in ALSPAC children
(N= 4251). The lines joining the circles display the results for
weighted allelic scores calculated by using genotyped variants from
across the genome before (unbroken line) and after pruning for
linkage disequilibrium (dashed line). The histogram in the
background displays the number of SNPs involved in construction
of the allelic score for the ‘‘All variants’’ condition at each
corresponding SNP inclusion threshold.
(PDF)
Figure S3 Association between polygene score and LDLc
measured at age nine in the ALSPAC cohort before and after
pruning for linkage disequilibrium. Association between polygene
score and LDLc measured at age nine using different p-value
thresholds for the construction of the score in ALSPAC children
(N= 4251). The lines joining the circles display the results for
unweighted allelic scores calculated by using genotyped variants
from across the genome before (unbroken line) and after pruning
for linkage disequilibrium (dashed line). The histogram in the
background displays the number of SNPs involved in construction
of the allelic score for the ‘‘All variants’’ condition at each
corresponding SNP inclusion threshold.
(PDF)
Figure S4 Association between polygene score and BMI
measured at age nine in the QIMR twins replication sample.
Association between polygene score and BMI using different p-
value thresholds for the construction of the score in unrelated
individuals from the QIMR twins cohort (N=4781). The lines
joining the circles display the results for allelic scores calculated by
using genotyped variants from across the genome in either a
weighted (unbroken line) or an unweighted (dashed line) fashion.
The lines joining the triangles display scores calculated similarly
but excluding all variants +/21 MB around 32 known BMI
variants, and using either a weighted (unbroken line) or
unweighted (dashed line) strategy. The histogram in the back-
ground displays the number of SNPs involved in construction of
the allelic score for the ‘‘All variants’’ condition at each
corresponding SNP inclusion threshold.
(PDF)
Figure S5 Association between polygene score and CRP
measured at age nine in the QIMR twins replication sample.
Association between polygene score and CRP using different p-
value thresholds for the construction of the score in unrelated
individuals from the QIMR twins cohort (N=2767). The lines
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joining the circles display the results for allelic scores calculated by
using genotyped variants from across the genome in either a
weighted (unbroken line) or an unweighted (dashed line) fashion.
The lines joining the triangles display scores calculated similarly
but excluding all variants +/21 MB around 18 known CRP
variants, and using either a weighted (unbroken line) or
unweighted (dashed line) strategy. The histogram in the back-
ground displays the number of SNPs involved in construction of
the allelic score for the ‘‘All variants’’ condition at each
corresponding SNP inclusion threshold.
(PDF)
Figure S6 Association between polygene score and LDLc
measured at age nine in the QIMR twins replication sample.
Association between polygene score and LDLc using different
p-value thresholds for the construction of the score in
unrelated individuals from the QIMR twins cohort
(N= 2630). The lines joining the circles display the results for
allelic scores calculated by using genotyped variants from
across the genome in either a weighted (unbroken line) or an
unweighted (dashed line) fashion. The lines joining the
triangles display scores calculated similarly but excluding all
variants +/21 MB around 37 known LDLc variants, and
using either a weighted (unbroken line) or unweighted (dashed
line) strategy. The histogram in the background displays the
number of SNPs involved in construction of the allelic score
for the ‘‘All variants’’ condition at each corresponding SNP
inclusion threshold.
(PDF)
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